Investigating how a specific enzyme repairs DNA damage in cancer cells

Biochemical reconstitution and inhibition of TMEJ

['FUNDING_P01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10868622

This study is looking at how a special protein called DNA polymerase θ helps fix broken DNA in cancer cells, which could help doctors find better ways to treat different types of tumors based on their unique features.

Quick facts

Phase['FUNDING_P01']
Study typeNih_funding
SexAll
SponsorUNIV OF NORTH CAROLINA CHAPEL HILL (nih funded)
Locations1 site (CHAPEL HILL, UNITED STATES)
Trial IDNIH-10868622 on ClinicalTrials.gov

What this research studies

This research focuses on understanding the role of DNA polymerase θ (Pol θ) in repairing DNA double-strand breaks, a critical process in cancer biology. The project aims to explore the molecular mechanisms of polymerase theta-mediated end joining (TMEJ) and how defects in this process can lead to vulnerabilities in tumors. By analyzing the structure and function of Pol θ, researchers will identify key components involved in the repair process and how different cancer genetic backgrounds affect responses to treatments targeting this enzyme. Patients may benefit from insights gained into how to better target cancer therapies based on their tumor's specific characteristics.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers that exhibit defects in DNA repair mechanisms, particularly those related to the BRCA1 gene.

Not a fit: Patients with cancers that do not involve DNA double-strand break repair mechanisms or those without genetic predispositions related to BRCA1 may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective cancer treatments by targeting specific vulnerabilities in tumors related to DNA repair mechanisms.

How similar studies have performed: Previous research has shown promising results in targeting DNA repair mechanisms in cancer, suggesting that this approach could lead to significant advancements in treatment.

Where this research is happening

CHAPEL HILL, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Breast Cancer 1 Gene, Breast Cancer 1 Gene Product, Breast Cancer Type 1 Susceptibility Gene

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.